Denali’s medicine and a similar one from Calico Life Sciences and AbbVie were not much different than a placebo, bringing the ...
Misses from amyotrophic lateral sclerosis hopefuls Denali Therapeutics and partners AbbVie and Calico Life Sciences mark the ...
AbbVie, Calico and Denali Therapeutics’ hopes of treating amyotrophic lateral sclerosis (ALS) by targeting eIF2B have all taken a hit. Massachusetts General Hospital found neither AbbVie and ...
In studies by Massachusetts General Hospital, the AbbVie-Calico collaborative drug and Denali Therapeutics' own drug failed to meet endpoints for treating amyotrophic lateral sclerosis, more widely ...
Amyotrophic lateral sclerosis, or ALS, causes nerve cells to degenerate and die, leading to muscle weakness.
A study of human brain organoids suggested a complex relationship between herpes simplex virus 1 infection and tau, suggesting that tau phosphorylation may act as an innate immune response in ...
The #ALS space—and the HEALEY ALS Platform Trial—saw two more failures this week, from Denali Therapeutics and AbbVie/Calico Life Sciences. After a disappointing 2024 for the space ...
It has collaboration and license agreements with Acorda Therapeutics, Inc.; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; Eisai ... It has collaborations with Calico Life Sciences LLC; ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback